Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN046 and Axitinib in Advanced Non-Small Cell Lung Cancer
NCT05420220Phase 2Completed
- Sponsor
- Alphamab Oncology
- Start
- Jul 2022
- Primary completion
- Dec 2024
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of erfonrilimab in non-small cell lung cancer (NSCLC) (3 cohorts), sponsored by Alphamab Oncology. Primary endpoint: Objective Response Rate at 2 years. Started Jul 2022; status: completed.
02
Drugs
erfonrilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05420220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05420220.